Although the participation of the immune system has been more profoundly studied in paclitaxel-induced neuropathy (see below), a previous study demonstrated that a single administration of oxaliplatin increased the levels of the chemokine, CCL2, and its receptor, CCR2, at the same time as mechanical hypersensitivity developed; pretreatment with the CCL2 antibody predictably prevented the development of allodynia (Illias et al., 2018). Here, CCR2 is linked to neuropathy.